Enliven Therapeutics, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 71.58 million compared to USD 37.66 million a year ago. Basic loss per share from continuing operations was USD 2.01 compared to USD 12.05 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
23.94 USD | +4.18% | +0.55% | +72.98% |
May. 20 | Enliven Therapeutics Insider Sold Shares Worth $22,877,262, According to a Recent SEC Filing | MT |
May. 14 | Enliven Therapeutics Q1 Loss Narrows | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+72.98% | 1.08B | |
+12.30% | 116B | |
+12.15% | 106B | |
-8.14% | 23.89B | |
-1.69% | 21.58B | |
-10.60% | 18.96B | |
-41.25% | 16.96B | |
-15.33% | 16.33B | |
+5.80% | 14.14B | |
+28.03% | 12.02B |
- Stock Market
- Equities
- ELVN Stock
- News Enliven Therapeutics, Inc.
- Enliven Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023